AU2018228873A1 - Diagnostic and therapeutic methods for cancer - Google Patents
Diagnostic and therapeutic methods for cancer Download PDFInfo
- Publication number
- AU2018228873A1 AU2018228873A1 AU2018228873A AU2018228873A AU2018228873A1 AU 2018228873 A1 AU2018228873 A1 AU 2018228873A1 AU 2018228873 A AU2018228873 A AU 2018228873A AU 2018228873 A AU2018228873 A AU 2018228873A AU 2018228873 A1 AU2018228873 A1 AU 2018228873A1
- Authority
- AU
- Australia
- Prior art keywords
- expression level
- sample
- genes
- esm1
- kdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 42
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 7
- 201000011510 cancer Diseases 0.000 title abstract description 12
- 238000002405 diagnostic procedure Methods 0.000 title abstract description 6
- 230000014509 gene expression Effects 0.000 claims abstract description 461
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 211
- 239000005557 antagonist Substances 0.000 claims abstract description 159
- 238000000034 method Methods 0.000 claims abstract description 141
- 230000027455 binding Effects 0.000 claims abstract description 103
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 73
- 238000011282 treatment Methods 0.000 claims abstract description 58
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract description 42
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 42
- 201000010982 kidney cancer Diseases 0.000 claims abstract description 42
- 229960003852 atezolizumab Drugs 0.000 claims abstract description 32
- 229960000397 bevacizumab Drugs 0.000 claims abstract description 31
- 208000006265 Renal cell carcinoma Diseases 0.000 claims abstract description 16
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims abstract description 15
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims abstract description 15
- 229960001796 sunitinib Drugs 0.000 claims abstract description 15
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims abstract description 11
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims abstract description 11
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims abstract description 11
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims abstract description 8
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims abstract description 5
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims abstract description 5
- 229960003005 axitinib Drugs 0.000 claims abstract description 5
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims abstract description 5
- 229960001292 cabozantinib Drugs 0.000 claims abstract description 5
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960000639 pazopanib Drugs 0.000 claims abstract description 5
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 45
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract 37
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract 37
- 239000000523 sample Substances 0.000 claims description 268
- 108090000623 proteins and genes Proteins 0.000 claims description 246
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 212
- 102100021860 Endothelial cell-specific molecule 1 Human genes 0.000 claims description 160
- 101000897959 Homo sapiens Endothelial cell-specific molecule 1 Proteins 0.000 claims description 160
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 160
- 101150054149 ANGPTL4 gene Proteins 0.000 claims description 158
- 108700042530 Angiopoietin-Like Protein 4 Proteins 0.000 claims description 158
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 claims description 158
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 158
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 158
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 158
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 154
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 154
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 122
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 122
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims description 120
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 claims description 120
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 120
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 120
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims description 120
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 claims description 120
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 120
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 120
- 102000004889 Interleukin-6 Human genes 0.000 claims description 120
- 108090001005 Interleukin-6 Proteins 0.000 claims description 120
- 102100026236 Interleukin-8 Human genes 0.000 claims description 120
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 120
- 102100030751 Eomesodermin homolog Human genes 0.000 claims description 106
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims description 106
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 claims description 106
- 102100037850 Interferon gamma Human genes 0.000 claims description 106
- 102100028467 Perforin-1 Human genes 0.000 claims description 106
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 84
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 66
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 66
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 65
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 65
- 102100030386 Granzyme A Human genes 0.000 claims description 65
- 102100030385 Granzyme B Human genes 0.000 claims description 65
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims description 65
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 65
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims description 65
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 claims description 65
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims description 63
- 102100027207 CD27 antigen Human genes 0.000 claims description 63
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 63
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 63
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 63
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 63
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims description 63
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 63
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 63
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 63
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 63
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims description 63
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 63
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 63
- 238000011319 anticancer therapy Methods 0.000 claims description 62
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 60
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 60
- 239000003153 chemical reaction reagent Substances 0.000 claims description 38
- 238000003556 assay Methods 0.000 claims description 28
- 230000008901 benefit Effects 0.000 claims description 20
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 17
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 17
- 238000003364 immunohistochemistry Methods 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 238000011529 RT qPCR Methods 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 108091008605 VEGF receptors Proteins 0.000 claims description 6
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229950009791 durvalumab Drugs 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 claims description 3
- 238000003559 RNA-seq method Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000012520 frozen sample Substances 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 238000010208 microarray analysis Methods 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 claims 82
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 82
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 claims 53
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 33
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 33
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 claims 27
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 claims 27
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 abstract description 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 abstract description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 abstract description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract description 4
- 201000005112 urinary bladder cancer Diseases 0.000 abstract description 4
- 206010006187 Breast cancer Diseases 0.000 abstract description 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 2
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 2
- 201000007270 liver cancer Diseases 0.000 abstract description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 2
- 201000005202 lung cancer Diseases 0.000 abstract description 2
- 208000020816 lung neoplasm Diseases 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- -1 CD27 Proteins 0.000 description 84
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 76
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 54
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 54
- 108010052500 Calgranulin A Proteins 0.000 description 54
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 54
- 102100032442 Protein S100-A8 Human genes 0.000 description 54
- 101710201246 Eomesodermin Proteins 0.000 description 53
- 108010052495 Calgranulin B Proteins 0.000 description 46
- 102100032420 Protein S100-A9 Human genes 0.000 description 46
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 39
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 30
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 28
- 102000011286 Antigen peptide transporter 2 Human genes 0.000 description 25
- 108010023338 Member 3 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 25
- 230000001976 improved effect Effects 0.000 description 9
- 238000002203 pretreatment Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000005166 vasculature Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- 102100037265 Podoplanin Human genes 0.000 description 3
- 101710118150 Podoplanin Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
- 102100033553 Delta-like protein 4 Human genes 0.000 description 2
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 description 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 2
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 2
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 101000946833 Homo sapiens T-cell surface glycoprotein CD8 beta chain Proteins 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 102100034928 T-cell surface glycoprotein CD8 beta chain Human genes 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000107 tumor biomarker Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003196 serial analysis of gene expression Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465547P | 2017-03-01 | 2017-03-01 | |
| US62/465,547 | 2017-03-01 | ||
| US201762514680P | 2017-06-02 | 2017-06-02 | |
| US62/514,680 | 2017-06-02 | ||
| US201762572979P | 2017-10-16 | 2017-10-16 | |
| US62/572,979 | 2017-10-16 | ||
| PCT/US2018/020460 WO2018160841A1 (en) | 2017-03-01 | 2018-03-01 | Diagnostic and therapeutic methods for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018228873A1 true AU2018228873A1 (en) | 2019-08-29 |
Family
ID=61692081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018228873A Abandoned AU2018228873A1 (en) | 2017-03-01 | 2018-03-01 | Diagnostic and therapeutic methods for cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11402382B2 (enExample) |
| EP (1) | EP3589754B1 (enExample) |
| JP (1) | JP7256127B2 (enExample) |
| KR (1) | KR20190134631A (enExample) |
| CN (1) | CN110546277B (enExample) |
| AU (1) | AU2018228873A1 (enExample) |
| CA (1) | CA3052670A1 (enExample) |
| ES (1) | ES2953595T3 (enExample) |
| IL (1) | IL268396A (enExample) |
| MX (1) | MX2019010295A (enExample) |
| PL (1) | PL3589754T3 (enExample) |
| TW (1) | TW201837467A (enExample) |
| WO (1) | WO2018160841A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2837428T3 (es) | 2016-01-08 | 2021-06-30 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3 |
| ES2953595T3 (es) | 2017-03-01 | 2023-11-14 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
| CN112955747A (zh) * | 2018-09-19 | 2021-06-11 | 豪夫迈·罗氏有限公司 | 膀胱癌的治疗和诊断方法 |
| CN112789684B (zh) * | 2018-10-01 | 2025-05-09 | 文塔纳医疗系统公司 | 用于预测对pd-1轴导向疗法的应答的方法和系统 |
| MX2021004709A (es) * | 2018-10-31 | 2021-06-04 | Genentech Inc | Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1. |
| CN117298270A (zh) * | 2018-11-06 | 2023-12-29 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途 |
| CN113366316B (zh) * | 2019-01-30 | 2025-05-23 | 国家医疗保健研究所 | 用于鉴定患有癌症的受试者是否将获得对免疫检查点抑制剂的应答的方法和组合物 |
| BR112021019365A2 (pt) * | 2019-03-29 | 2021-11-30 | Genentech Inc | Métodos para identificar um indivíduo que tem câncer, para selecionar uma terapia, para identificar uma interação proteína-proteína e para identificar um modulador, métodos de tratamento de um indivíduo com câncer, de identificação, de seleção de uma terapia e de identificação de um modulador, coleções de polipeptídeos, de vetores e de células e moduladores isolados |
| US20220241263A1 (en) * | 2019-06-01 | 2022-08-04 | Ares Trading S.A. | Pd-1 axis binding antagonist to treat cancer with genetic mutations in specific genes |
| CN113905761A (zh) * | 2019-06-10 | 2022-01-07 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗驱动基因阳性肺癌的联用药物组合物 |
| TW202114665A (zh) * | 2019-08-05 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種吡咯并六員雜環化合物在製備治療ｆｇｆｒ２基因變異的腫瘤的藥物中的用途 |
| US20220380854A1 (en) * | 2019-11-04 | 2022-12-01 | Merck Sharp & Dohme Corp. | ANGIOGENESIS AND mMDSC GENE EXPRESSION BASED BIOMARKER OF TUMOR RESPONSE TO PD-1 ANTAGONISTS |
| BR112022010069A2 (pt) * | 2019-11-25 | 2022-09-06 | Akeso Biopharma Inc | Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica |
| CN113117072A (zh) * | 2020-01-14 | 2021-07-16 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| CN115052605B (zh) * | 2020-03-09 | 2024-07-05 | 和记黄埔医药（上海）有限公司 | 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法 |
| WO2021202959A1 (en) * | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| US20230184771A1 (en) * | 2020-04-21 | 2023-06-15 | Board Of Regents, The University Of Texas System | Methods for treating bladder cancer |
| AU2021262368A1 (en) * | 2020-04-30 | 2022-12-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination drug for treating kidney cancer |
| SE2050559A1 (en) * | 2020-05-13 | 2021-11-14 | Khs Biomedinvent Ab | PD-1 as a predictive marker for therapy in cancer |
| WO2022040555A2 (en) * | 2020-08-21 | 2022-02-24 | Exelixis, Inc. | Method of treating cancer |
| WO2022042537A1 (zh) * | 2020-08-24 | 2022-03-03 | 江苏恒瑞医药股份有限公司 | TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途 |
| KR102544915B1 (ko) | 2020-12-02 | 2023-06-16 | 한국교통대학교산학협력단 | 활성산소 또는 글루타치온 인지형 무선 진단용 폴리머 닷 기반 하이드로겔 센서 제조방법 |
| CN113144189B (zh) * | 2021-03-11 | 2022-07-12 | 山东先声生物制药有限公司 | Vegf抗体与免疫检查点抑制剂的联用 |
| EP4370713A1 (en) | 2021-07-15 | 2024-05-22 | Vib Vzw | Biomarkers predicting response of breast cancer to immunotherapy |
| IL310877A (en) | 2021-08-16 | 2024-04-01 | Insitro Inc | Discovery platform |
| WO2023080900A1 (en) * | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| KR102401657B1 (ko) * | 2021-11-12 | 2022-05-26 | 주식회사 마노바이오 | 동반진단용 암 조직 내 보체 c7 바이오마커 조성물 및 이의 용도 |
| AU2022391029B2 (en) | 2021-11-19 | 2025-11-06 | Insitro, Inc. | Autonomous cell imaging and modeling system |
| TWI817329B (zh) * | 2022-01-20 | 2023-10-01 | 長庚大學 | 腎臟罹癌風險之判斷方法 |
| CN115575620A (zh) * | 2022-03-25 | 2023-01-06 | 复旦大学附属中山医院 | 一种癌症免疫治疗疗效和预后预测试剂盒 |
| CN115414486A (zh) * | 2022-08-08 | 2022-12-02 | 复旦大学 | Vegfa信号以及fgf-2信号双效抑制剂、fgf-2信号抑制剂的新用途 |
| WO2024145643A1 (en) * | 2022-12-30 | 2024-07-04 | The Regents Of The University Of California | Methods and compositions of in vivo engineering of t-cells to anti-inflammatory cells and therapeutic applications there of |
| WO2024173610A1 (en) * | 2023-02-15 | 2024-08-22 | Insitro, Inc. | Machine-learning-enabled predictive biomarker discovery and patient stratification using standard-of-care data |
| WO2025184858A1 (en) * | 2024-03-07 | 2025-09-12 | Biotheus Inc. | Combination therapy comprising a bispecific anti-vegf-a and anti-pd-l1 antibody and a chemotherapy for cancer treatment |
| WO2025185733A1 (en) * | 2024-03-07 | 2025-09-12 | Biotheus Inc. | Combination therapy comprising a pd-1/pd-l1 and vegf/vegfr binding agent and a chemotherapy for cancer treatment |
| WO2025185161A1 (en) * | 2024-03-07 | 2025-09-12 | Biotheus Inc. | Combination therapy comprising a bispecific anti-vegf-a and anti-pd-l1 antibody and a chemotherapy for cancer treatment |
Family Cites Families (192)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US533A (en) | 1837-12-26 | Truss for hermta | ||
| US4943A (en) | 1847-01-26 | Harness-buckle | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE135373T1 (de) | 1989-09-08 | 1996-03-15 | Univ Johns Hopkins | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| PT659439E (pt) | 1993-12-24 | 2002-04-29 | Merck Patent Gmbh | Imunoconjugados |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| KR100437582B1 (ko) | 1995-07-06 | 2004-12-17 | 노파르티스 아게 | 피롤로피리미딘및그들의제조방법 |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2361267T3 (es) | 1997-04-07 | 2011-06-15 | Genentech Inc. | Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria. |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| PT980244E (pt) | 1997-05-06 | 2003-10-31 | Wyeth Corp | Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| IL135622A0 (en) | 1997-11-06 | 2001-05-20 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| PT1131304E (pt) | 1998-11-19 | 2003-04-30 | Warner Lambert Co | N-¬4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quinazolin-6-il|-acrilamida um inibidor irreversivel de tirosino quinases |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| DK1242438T3 (da) | 1999-12-29 | 2007-02-12 | Immunogen Inc | Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse |
| ATE360430T1 (de) | 2000-02-14 | 2007-05-15 | Univ California | Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
| US7038015B2 (en) | 2001-04-06 | 2006-05-02 | Maxygen Holdings, Ltd. | Interferon gamma polypeptide variants |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| IL159894A0 (en) | 2001-07-17 | 2004-06-20 | Res Dev Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| NZ532526A (en) | 2001-10-25 | 2007-01-26 | Genentech Inc | Compositions comprising a glycoprotein having a Fc region |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| MXPA04009924A (es) | 2002-04-09 | 2005-07-01 | Kyowa Hakko Kogyo Kk | Celulas de genoma modificado. |
| JP4628679B2 (ja) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞 |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AR042485A1 (es) | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| EP1640452A4 (en) | 2003-05-30 | 2009-12-23 | Nippon Shinyaku Co Ltd | OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
| TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
| CN104998273A (zh) | 2003-11-06 | 2015-10-28 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| EP3088004B1 (en) | 2004-09-23 | 2018-03-28 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US8219149B2 (en) | 2005-06-29 | 2012-07-10 | Nokia Corporation | Mobile communication terminal |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CA2650507A1 (en) | 2006-04-27 | 2007-11-08 | Universite De Montreal | Assessment and reduction of risk of graft-versus-host disease |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| EP2944651B1 (en) | 2007-10-02 | 2018-01-31 | Universität zu Köln | Novel marker genes for regulatory t cells from human blood |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| WO2010025216A1 (en) | 2008-08-27 | 2010-03-04 | H. Lundbeck A/S | System and methods for measuring biomarker profiles |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| SG177640A1 (en) | 2009-07-13 | 2012-02-28 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer |
| JP2013501526A (ja) | 2009-08-14 | 2013-01-17 | ジェネンテック， インコーポレイテッド | Ｖｅｇｆアンタゴニストに対する患者の応答をモニターするための生物学的マーカー |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| NZ719474A (en) | 2010-01-11 | 2018-07-27 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| WO2011094483A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| AU2012287024A1 (en) | 2011-07-22 | 2014-02-20 | Pawel Kalinski | Tumor selective chemokine modulation |
| MX356802B (es) | 2012-01-13 | 2018-06-13 | Genentech Inc | Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf. |
| KR102129636B1 (ko) | 2012-05-31 | 2020-07-03 | 제넨테크, 인크. | Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법 |
| EP2872646B1 (en) | 2012-07-12 | 2017-08-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| EP2880180B1 (en) | 2012-08-06 | 2018-10-03 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and kits for screening patients with a cancer |
| EP3552628A1 (en) | 2012-09-07 | 2019-10-16 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
| WO2014087156A1 (en) | 2012-12-03 | 2014-06-12 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| KR20150131269A (ko) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| US20150071910A1 (en) * | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| SG11201600310QA (en) | 2013-07-16 | 2016-02-26 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| EP3102605B1 (en) * | 2014-02-04 | 2018-11-14 | Pfizer Inc | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| JP2017507155A (ja) | 2014-03-05 | 2017-03-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
| WO2015157655A2 (en) * | 2014-04-10 | 2015-10-15 | University Of Tennessee Research Foundation | Method for predicting response to vegf targeted therapeutics |
| GB201408091D0 (en) | 2014-05-07 | 2014-06-18 | Univ Edinburgh | Methods and uses |
| JP2018503373A (ja) | 2014-12-30 | 2018-02-08 | ジェネンテック， インコーポレイテッド | がんの予後診断及び治療のための方法及び組成物 |
| RS61152B2 (sr) | 2015-05-12 | 2024-06-28 | Hoffmann La Roche | Terapeutski i dijagnostički postupci za lečenje raka |
| HK1248773A1 (zh) | 2015-05-29 | 2018-10-19 | 豪夫迈‧罗氏有限公司 | 用於癌症的治疗和诊断方法 |
| JP2018518483A (ja) * | 2015-06-08 | 2018-07-12 | ジェネンテック， インコーポレイテッド | 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法 |
| US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| CN105256036B (zh) * | 2015-10-26 | 2019-02-12 | 中国人民解放军第二军医大学 | 一种检测血清中lncARSR的试剂盒及其在检测肾癌舒尼替尼耐药中的应用 |
| CA3020718A1 (en) * | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
| JP7503887B2 (ja) | 2016-04-15 | 2024-06-21 | ジェネンテック， インコーポレイテッド | がんを監視及び治療するための方法 |
| EP3518928A1 (en) | 2016-09-27 | 2019-08-07 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| ES2953595T3 (es) | 2017-03-01 | 2023-11-14 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
| JP2020516253A (ja) | 2017-04-14 | 2020-06-11 | ジェネンテック， インコーポレイテッド | がんのための診断及び治療方法 |
| AU2019361983A1 (en) | 2018-10-18 | 2021-05-20 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
-
2018
- 2018-03-01 ES ES18712321T patent/ES2953595T3/es active Active
- 2018-03-01 EP EP18712321.1A patent/EP3589754B1/en active Active
- 2018-03-01 MX MX2019010295A patent/MX2019010295A/es unknown
- 2018-03-01 PL PL18712321.1T patent/PL3589754T3/pl unknown
- 2018-03-01 JP JP2019542177A patent/JP7256127B2/ja active Active
- 2018-03-01 TW TW107106881A patent/TW201837467A/zh unknown
- 2018-03-01 CN CN201880024739.2A patent/CN110546277B/zh active Active
- 2018-03-01 CA CA3052670A patent/CA3052670A1/en active Pending
- 2018-03-01 WO PCT/US2018/020460 patent/WO2018160841A1/en not_active Ceased
- 2018-03-01 AU AU2018228873A patent/AU2018228873A1/en not_active Abandoned
- 2018-03-01 KR KR1020197028634A patent/KR20190134631A/ko not_active Ceased
-
2019
- 2019-07-31 IL IL268396A patent/IL268396A/en unknown
- 2019-08-20 US US16/545,177 patent/US11402382B2/en active Active
-
2022
- 2022-06-08 US US17/835,418 patent/US12078638B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110546277B (zh) | 2024-06-11 |
| EP3589754B1 (en) | 2023-06-28 |
| US11402382B2 (en) | 2022-08-02 |
| JP7256127B2 (ja) | 2023-04-11 |
| IL268396A (en) | 2019-09-26 |
| PL3589754T3 (pl) | 2023-10-09 |
| JP2020513788A (ja) | 2020-05-21 |
| US20230082122A1 (en) | 2023-03-16 |
| KR20190134631A (ko) | 2019-12-04 |
| MX2019010295A (es) | 2019-11-21 |
| WO2018160841A1 (en) | 2018-09-07 |
| US12078638B2 (en) | 2024-09-03 |
| TW201837467A (zh) | 2018-10-16 |
| ES2953595T3 (es) | 2023-11-14 |
| CA3052670A1 (en) | 2018-09-07 |
| CN110546277A (zh) | 2019-12-06 |
| US20190369098A1 (en) | 2019-12-05 |
| EP3589754A1 (en) | 2020-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12078638B2 (en) | Diagnostic and therapeutic methods for cancer | |
| US20230340613A1 (en) | Methods for monitoring and treating cancer | |
| US11535671B2 (en) | Therapeutic and diagnostic methods for cancer | |
| EP3294770B1 (en) | Therapeutic and diagnostic methods for cancer | |
| US20190038734A1 (en) | Methods for monitoring and treating cancer | |
| US20210253710A1 (en) | Diagnostic and therapeutic methods for kidney cancer | |
| US20240060135A1 (en) | Therapeutic and diagnostic methods for cancer | |
| HK40018953B (zh) | 用於癌症的诊断和治疗方法 | |
| HK40018953A (en) | Diagnostic and therapeutic methods for cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |